ClinicalTrials.gg
CompletedNCT03421431Updated Sep 16, 2021Results posted

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

A Phase 2 interventional study of EDP-305 Dose 1 and EDP-305 Dose 2 in Non-Alcoholic Steatohepatitis, sponsored by Enanta Pharmaceuticals, Inc. Completed at 82 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
118th of 460
134 · median 56
Started
2018
with 35 others
Phase 2
192 of 547
15 open now
Registered
227th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 118th largest by enrollment of the 460 interventional ones that give a count, is one of 36 that started in 2018, is one of 192 in phase 2, and was the 227th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with Non-Alcoholic Steatohepatitis

03

Conditions studied

  • Non-Alcoholic Steatohepatitis

Keywords

  • NASH
  • Non-Alcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document must be signed and dated by the subject
  • Male and female subjects of any ethnic origin between the ages of 18 and 75 years, inclusive
  • Male or female with presence of NASH by:

    • Histologic evidence on a historical liver within 24 months of Screening consistent with NASH with fibrosis (no cirrhosis), and elevated at Screening AND Screening MRI PDFF with >8 % steatosis OR
    • Phenotypic diagnosis of NASH based on elevated ALT and diagnosis of T2DM or pre-diabetes AND Screening MRI PDFF with >8 % steatosis
  • (BMI) >25 kg/m2; for Asian-Americans, BMI >23 kg/m2
  • Female subjects of must agree to use two effective methods of from the date of Screening until 90 days after the last dose of EDP-305.
  • Subject must be willing and able to adhere to the assessments, visit schedules, prohibitions and restrictions, as described in this protocol

Exclusion criteria

Exclusion Criteria:

  • Laboratory Screening Results:

    • Total > (normal range 0.2-1.2 mg/dL)
    • Total white blood cells (WBC) \<3,000 cells/mm3
    • (ANC) \<1,500 cells/mm3
    • count \<140,000/mm3
    • (international normalized ratio, INR) > 1.2
    • Creatine kinase above the upper limit of normal (ULN) except when in relation with intense exercise
    • Serum creatinine >2 mg/dL or \<60 ml/min (based on Cockroft Gault method)
  • Known history of alpha-1-antitrypsin deficiency
  • Use of an experimental treatment for NASH within the past 6 months
  • Use of (eg, ) for more than 2 weeks in duration within 1 year prior to Screening and during the course of the study
  • Use of experimental or unapproved drugs within a year of Screening
  • Any other condition(s) (including cardiovascular diseases) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Principal Investigator (PI)
  • Pregnant or nursing females
  • Recipients of liver or other organ transplantation or anticipated need for orthotropic organ transplantation in one year as determined by a Model for End-Stage Liver Disease (MELD) Score ≥ 15
  • Clinical suspicion of advanced liver disease or cirrhosis
  • Coexisting liver or biliary diseases, such as primary sclerosing cholangitis (PSC), choledocholithiasis, acute or chronic hepatitis, hepatitis, alcoholic liver disease, acute infection of bile duct system or gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension), cirrhosis
  • Suspicion of cancer (eg, liver cancer) with the exception of basal cell carcinoma that has been resected
  • Cirrhosis with or without complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, bilirubin > 2xULN
  • Hepatorenal syndrome (type I or II) or Screening serum creatinine > 2 mg/dL (178 μmol/L)
  • Prior variceal hemorrhage, uncontrolled encephalopathy, Class A, B, and C, esophageal varices, or ascites within the previous 6 months of Screening (defined as date signed)
  • Any condition possibly affecting drug absorption (eg, gastrectomy \<3 years prior to Screening)
  • Subject has received an agent or vaccine within 30 days, or a biological product within 3 months or 5 elimination half-lives (whichever is longer) prior to the planned intake of study drug. NOTE: Flu vaccine will be allowed upon Medical Monitor's approval
  • Use of a new statin regimen from Screening and throughout study duration. NOTE: Subjects on a stable dose of statins for at least three months prior to Screening are allowed. No dose modification during the study will be allowed.
  • Current use of fibrates. Note: Subjects who discontinued fibrates for at least 3 months before Screening can participate
  • history of drug sensitivity or allergy, as determined by the PI
  • Uncontrolled diabetes mellitus (ie, ≥9% or higher) 60 days prior to Day 1
  • Subjects with to MRI imaging, or not being able to have the MRI performed
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    EDP-305 Dose 1

    Subjects will take 2 tablets once a day orally for 12 weeks

    Drug: EDP-305 Dose 1

  • Experimental
    EDP-305 Dose 2

    Subjects will take 2 tablets once a day orally for 12 weeks

    Drug: EDP-305 Dose 2

  • Placebo comparator
    Placebo

    Subjects will take 2 tablets once a day orally for 12 weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ALT level. Baseline refers to the average of the screening and the Day 1 values; if either the screening or Day 1 values were missing, the non-missing value was used. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Mean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12

    The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  2. Mean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the aspartate aminotransferase (AST) level and platelet count. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. APRI is calculated from the level of AST measured in a blood test (international units per liter \[IU/L\]) and platelet count (10\^9/L) according to the following formula: APRI = (\[AST value in IU/L / upper limit of the normal range of AST\] / \[platelet count in 10\^9/L\]) × 100. In general, APRI scores range from 0 to \>2.0, where scores \<0.5 indicate no significant fibrosis, scores \>1.5 indicate significant fibrosis, and scores \>2.0 have been shown to be best correlated with the presence of cirrhosis. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  3. Mean Change From Baseline in Triglycerides (TG) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the TG level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  4. Mean Change From Baseline in Total Cholesterol at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the total cholesterol level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  5. Mean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  6. Mean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the LDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  7. Mean Change From Baseline in Adiponectin at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the adiponectin level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  8. Mean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoA-1 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  9. Mean Change From Baseline in Apolipoproteins B (ApoB) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoB level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  10. Mean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoC3 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  11. Mean Change From Baseline in Fasting Blood Glucose at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting glucose level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  12. Mean Change From Baseline in Fasting Insulin at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting insulin (in micro International units per milliliter \[μIU/mL\]). Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  13. Mean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were not considered as having type 2 diabetes mellitus (T2DM) were identified as nondiabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  14. Mean Change From Baseline in HOMA Index for Diabetic Participants at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were considered as having T2DM were identified as diabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  15. Mean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 12

    Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HbA1c. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  16. Maximum Plasma Concentration (Cmax) of EDP-305 on Day 1 and Week 12

    The Cmax is the maximum observed plasma concentration, which was measured for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the Pharmacokinetic (PK) Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  17. Time to Reach Maximum Plasma Concentration (Tmax) of EDP-305 on Day 1 and at Week 12

    The Tmax was measured for EDP-305 on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  18. Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[Last]) of EDP-305 on Day 1 and at Week 12

    AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  19. Cmax of EP-022571 on Day 1 and at Week 12

    The Cmax is the maximum observed plasma concentration, which was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  20. Tmax of EP-022571 on Day 1 and at Week 12

    The Tmax was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  21. AUC(Last) of EP-022571 on Day 1 and at Week 12

    AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  22. Cmax of EP-022572 on Day 1 and at Week 12

    The Cmax is the maximum observed plasma concentration, which was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  23. Tmax of EP-022572 on Day 1 and at Week 12

    The Tmax was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  24. AUC(Last) of EP-022572 on Day 1 and at Week 12

    AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  25. Cmax of EP-022679 on Day 1 and at Week 12

    The Cmax is the maximum observed plasma concentration, which was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  26. Tmax of EP-022679 on Day 1 and at Week 12

    The Tmax was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  27. AUC(Last) of EP-022679 on Day 1 and at Week 12

    AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)

  28. Mean Change From Baseline in Body Weight at Week 12

    Body weight was measured at specific timepoints for the participants. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  29. Mean Change From Baseline in Waist to Hip (WTH) Ratio at Week 12

    The WTH ratio is calculated as the ratio of waist to hip circumference, which was measured at specific timepoints. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Baseline and Week 12

  30. Mean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12

    Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)

  31. Mean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 12

    Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)

  32. Mean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12

    Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)

  33. Mean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12

    Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)

  34. Mean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 12

    Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)

  35. Mean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 12

    Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

    Time frame: Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)

07

Results

Posted Sep 16, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboEDP-305 1 mgEDP-305 2.5 mg
Started245553
Completed184939
Not completed6614
Withdrew: Adverse event2112
Withdrew: Lost to follow-up111
Withdrew: Withdrawal by subject321
Withdrew: Protocol violation010
Withdrew: Participant met stopping rules010

Outcome measures

PrimaryMean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ALT level. Baseline refers to the average of the screening and the Day 1 values; if either the screening or Day 1 values were missing, the non-missing value was used. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · units per liter (U/L)
Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12
units per liter (U/L)PlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline (Average) in Alanine Aminotransferase (ALT) at Week 12-13.85 ± 18.151-23.76 ± 28.135-26.14 ± 33.328
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0495 · Least squares (ls) mean difference: 12.460 · 95% CI 0.029 to 24.891
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.3039 · Ls mean difference: 6.257 · 95% CI -5.754 to 18.268
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.2130 · Ls mean difference: 6.203 · 95% CI -3.615 to 16.021
SecondaryMean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12

The liver fat percentage was assessed by MRI-PDFF, which is an established method that enables the quantification of fat content in the liver; the value of liver fat is expressed in percentage and ranges from 0 to 100% with higher values representing higher liver fat level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · percentage of fat
Mean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12
percentage of fatPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) at Week 12-2.842 ± 4.4687-3.759 ± 5.1600-6.428 ± 7.2586
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0009 · Ls mean difference: 4.717 · 95% CI 1.980 to 7.455
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.4946 · Ls mean difference: 0.934 · 95% CI -1.766 to 3.635
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.0005 · Ls mean difference: 3.783 · 95% CI 1.708 to 5.858
SecondaryMean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the aspartate aminotransferase (AST) level and platelet count. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. The APRI score (AST to platelet ratio index) is an index comprised of biochemical values and is used to determine the degree of hepatic fibrosis. APRI is calculated from the level of AST measured in a blood test (international units per liter \[IU/L\]) and platelet count (10\^9/L) according to the following formula: APRI = (\[AST value in IU/L / upper limit of the normal range of AST\] / \[platelet count in 10\^9/L\]) × 100. In general, APRI scores range from 0 to \>2.0, where scores \<0.5 indicate no significant fibrosis, scores \>1.5 indicate significant fibrosis, and scores \>2.0 have been shown to be best correlated with the presence of cirrhosis. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · ratio
Mean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12
ratioPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Aspartate Aminotransferase to Platelet Ratio Index (APRI) at Week 12-0.180 ± 0.3462-0.107 ± 0.3396-0.194 ± 0.3533
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.2756 · Ls mean difference: 0.076 · 95% CI -0.062 to 0.214
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.9686 · Ls mean difference: -0.003 · 95% CI -0.136 to 0.131
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.1406 · Ls mean difference: 0.079 · 95% CI -0.026 to 0.184
SecondaryMean Change From Baseline in Triglycerides (TG) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the TG level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Triglycerides (TG) at Week 12
millimoles per liter (mmol/L)PlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Triglycerides (TG) at Week 12-0.151 ± 0.8529-0.366 ± 1.58580.129 ± 1.1088
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.6130 · Ls mean difference: -0.125 · 95% CI -0.613 to 0.363
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.8366 · Ls mean difference: -0.049 · 95% CI -0.521 to 0.423
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.7015 · Ls mean difference: -0.076 · 95% CI -0.466 to 0.315
SecondaryMean Change From Baseline in Total Cholesterol at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the total cholesterol level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmol/L
Mean Change From Baseline in Total Cholesterol at Week 12
mmol/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Total Cholesterol at Week 12-0.175 ± 0.68790.046 ± 0.6697-0.003 ± 1.0046
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.3875 · Ls mean difference: -0.186 · 95% CI -0.613 to 0.240
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.2331 · Ls mean difference: -0.248 · 95% CI -0.657 to 0.162
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.7164 · Ls mean difference: 0.061 · 95% CI -0.272 to 0.395
SecondaryMean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmol/L
Mean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
mmol/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 120.008 ± 0.1279-0.058 ± 0.1670-0.210 ± 0.2708
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = <0.0001 · Ls mean difference: 0.210 · 95% CI 0.110 to 0.311
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.3480 · Ls mean difference: 0.046 · 95% CI -0.051 to 0.143
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = <0.0001 · Ls mean difference: 0.164 · 95% CI 0.085 to 0.243
SecondaryMean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the LDL-C level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmol/L
Mean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
mmol/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12-0.112 ± 0.64310.129 ± 0.50990.151 ± 0.8157
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0897 · Ls mean difference: -0.299 · 95% CI -0.645 to 0.047
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.1411 · Ls mean difference: -0.251 · 95% CI -0.586 to 0.085
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.7330 · Ls mean difference: -0.048 · 95% CI -0.326 to 0.230
SecondaryMean Change From Baseline in Adiponectin at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the adiponectin level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · nanogram per milliliter (ng/mL)
Mean Change From Baseline in Adiponectin at Week 12
nanogram per milliliter (ng/mL)PlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Adiponectin at Week 12319.16 ± 689.38717.94 ± 828.494522.00 ± 2649.701
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.9143 · Ls mean difference: 51.873 · 95% CI -901.574 to 1005.320
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.3718 · Ls mean difference: 404.168 · 95% CI -489.519 to 1297.854
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.3466 · Ls mean difference: -352.295 · 95% CI -1091.308 to 386.719
SecondaryMean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoA-1 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · proteins*10^9/L
Mean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12
proteins*10^9/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Apolipoproteins A1 (ApoA-1) at Week 12-0.074 ± 0.1514-0.107 ± 0.1671-0.226 ± 0.2197
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0003 · Ls mean difference: 0.173 · 95% CI 0.081 to 0.264
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.5685 · Ls mean difference: 0.025 · 95% CI -0.062 to 0.113
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = <0.0001 · Ls mean difference: 0.147 · 95% CI 0.075 to 0.219
SecondaryMean Change From Baseline in Apolipoproteins B (ApoB) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoB level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · proteins*10^9/L
Mean Change From Baseline in Apolipoproteins B (ApoB) at Week 12
proteins*10^9/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Apolipoproteins B (ApoB) at Week 12-0.028 ± 0.16870.040 ± 0.17810.099 ± 0.2898
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0282 · Ls mean difference: -0.133 · 95% CI -0.252 to -0.015
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.2412 · Ls mean difference: -0.068 · 95% CI -0.182 to 0.046
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.1649 · Ls mean difference: -0.066 · 95% CI -0.158 to 0.027
SecondaryMean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the ApoC3 level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · proteins*10^9/L
Mean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12
proteins*10^9/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Apolipoproteins C3 (ApoC3) at Week 12-0.0094 ± 0.04388-0.0167 ± 0.03918-0.0122 ± 0.05721
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.4357 · Ls mean difference: 0.009 · 95% CI -0.014 to 0.032
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.8989 · Ls mean difference: 0.001 · 95% CI -0.021 to 0.023
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.4120 · Ls mean difference: 0.008 · 95% CI -0.011 to 0.026
SecondaryMean Change From Baseline in Fasting Blood Glucose at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting glucose level. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmol/L
Mean Change From Baseline in Fasting Blood Glucose at Week 12
mmol/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Fasting Blood Glucose at Week 12-0.11 ± 2.1300.48 ± 1.8471.68 ± 3.396
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0134 · Ls mean difference: -1.731 · 95% CI -3.095 to -0.368
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.6263 · Ls mean difference: -0.327 · 95% CI -1.656 to 1.001
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.0115 · Ls mean difference: -1.404 · 95% CI -2.487 to -0.322
SecondaryMean Change From Baseline in Fasting Insulin at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the fasting insulin (in micro International units per milliliter \[μIU/mL\]). Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · μIU/mL
Mean Change From Baseline in Fasting Insulin at Week 12
μIU/mLPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Fasting Insulin at Week 12-0.688 ± 9.28082.528 ± 14.6947-5.635 ± 52.7637
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.4608 · Ls mean difference: -3.723 · 95% CI -13.700 to 6.253
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.6238 · Ls mean difference: -2.377 · 95% CI -11.962 to 7.207
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.7367 · Ls mean difference: -1.346 · 95% CI -9.268 to 6.576
SecondaryMean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were not considered as having type 2 diabetes mellitus (T2DM) were identified as nondiabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 12
units on a scalePlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Homeostasis Model Assessment (HOMA) Index for Nondiabetic Participants at Week 120.587 ± 2.00880.192 ± 2.7180-6.474 ± 24.9369
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.8302 · Ls mean difference: -0.407 · 95% CI -4.287 to 3.474
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.5053 · Ls mean difference: -1.280 · 95% CI -5.192 to 2.632
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.4760 · Ls mean difference: 0.873 · 95% CI -1.620 to 3.366
SecondaryMean Change From Baseline in HOMA Index for Diabetic Participants at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation; from the results of fasting glucose and insulin, an insulin resistance (IR) was estimated for the nondiabetic participants using the HOMA-IR computer algorithm. A higher HOMA-IR indicates a higher degree of insulin resistance. Participants who were considered as having T2DM were identified as diabetic. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in HOMA Index for Diabetic Participants at Week 12
units on a scalePlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in HOMA Index for Diabetic Participants at Week 12-0.493 ± 6.26242.088 ± 6.61145.059 ± 15.0113
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0639 · Ls mean difference: -5.910 · 95% CI -12.171 to 0.351
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.4884 · Ls mean difference: -2.064 · 95% CI -7.971 to 3.843
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.1532 · Ls mean difference: -3.846 · 95% CI -9.156 to 1.464
SecondaryMean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 12

Blood samples were collected at specific timepoints for the laboratory evaluation to assess the HbA1c. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · percentage of glycated hemoglobin
Mean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 12
percentage of glycated hemoglobinPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Glycated Hemoglobin (HbA1c) in Participants With T2DM at Week 120.31 ± 0.6850.21 ± 0.7760.76 ± 0.963
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0811 · Ls mean difference: -0.460 · 95% CI -0.978 to 0.058
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.6312 · Ls mean difference: 0.117 · 95% CI -0.367 to 0.601
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.0099 · Ls mean difference: -0.577 · 95% CI -1.011 to -0.143
SecondaryMaximum Plasma Concentration (Cmax) of EDP-305 on Day 1 and Week 12

The Cmax is the maximum observed plasma concentration, which was measured for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the Pharmacokinetic (PK) Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of EDP-305 on Day 1 and Week 12
ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 111.1 ± 10525.1 ± 101
Week 1215.9 ± 10541.1 ± 101
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of EDP-305 on Day 1 and at Week 12

The Tmax was measured for EDP-305 on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Median · hours (h)
Time to Reach Maximum Plasma Concentration (Tmax) of EDP-305 on Day 1 and at Week 12
hours (h)EDP-305 1 mgEDP-305 2.5 mg
Day 16.00 (2.00 to 8.07)6.00 (2.00 to 8.25)
Week 126.00 (0.00 to 8.02)6.00 (0.00 to 8.18)
SecondaryArea Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[Last]) of EDP-305 on Day 1 and at Week 12

AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EDP-305 on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · hour*nanogram per milliliter (h*ng/mL)
Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[Last]) of EDP-305 on Day 1 and at Week 12
hour*nanogram per milliliter (h*ng/mL)EDP-305 1 mgEDP-305 2.5 mg
Day 153.6 ± 101129 ± 100
Week 1287.2 ± 101264 ± 100
SecondaryCmax of EP-022571 on Day 1 and at Week 12

The Cmax is the maximum observed plasma concentration, which was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · ng/mL
Cmax of EP-022571 on Day 1 and at Week 12
ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 10.324 ± 9830.833 ± 177
Week 120.296 ± 15490.787 ± 233
SecondaryTmax of EP-022571 on Day 1 and at Week 12

The Tmax was measured for EP-022571 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Median · h
Tmax of EP-022571 on Day 1 and at Week 12
hEDP-305 1 mgEDP-305 2.5 mg
Day 16.00 (2.00 to 8.00)6.00 (1.93 to 8.25)
Week 126.00 (0.00 to 8.00)6.00 (0.00 to 6.15)
SecondaryAUC(Last) of EP-022571 on Day 1 and at Week 12

AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022571 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · h*ng/mL
AUC(Last) of EP-022571 on Day 1 and at Week 12
h*ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 11.48 ± 1743.77 ± 112
Week 121.41 ± 187.013.81 ± 121.18
SecondaryCmax of EP-022572 on Day 1 and at Week 12

The Cmax is the maximum observed plasma concentration, which was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · ng/mL
Cmax of EP-022572 on Day 1 and at Week 12
ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 10.234 ± 19420.571 ± 212
Week 120.214 ± 28630.556 ± 212
SecondaryTmax of EP-022572 on Day 1 and at Week 12

The Tmax was measured for EP-022572 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Median · h
Tmax of EP-022572 on Day 1 and at Week 12
hEDP-305 1 mgEDP-305 2.5 mg
Day 16.00 (2.00 to 8.07)6.00 (2.00 to 8.00)
Week 126.00 (0.00 to 8.00)2.05 (0.00 to 8.18)
SecondaryAUC(Last) of EP-022572 on Day 1 and at Week 12

AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022572 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · h*ng/mL
AUC(Last) of EP-022572 on Day 1 and at Week 12
h*ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 11.06 ± 2202.92 ± 114
Week 121.13 ± 2123.19 ± 116
SecondaryCmax of EP-022679 on Day 1 and at Week 12

The Cmax is the maximum observed plasma concentration, which was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · ng/mL
Cmax of EP-022679 on Day 1 and at Week 12
ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 10.574 ± 3211.28 ± 167
Week 121.41 ± 1173.85 ± 122
SecondaryTmax of EP-022679 on Day 1 and at Week 12

The Tmax was measured for EP-022679 (a metabolite of EDP-305) on Day 1 and at Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Median · h
Tmax of EP-022679 on Day 1 and at Week 12
hEDP-305 1 mgEDP-305 2.5 mg
Day 18.00 (5.88 to 8.00)8.00 (6.00 to 8.25)
Week 126.03 (0.00 to 8.00)6.00 (0.00 to 8.18)
SecondaryAUC(Last) of EP-022679 on Day 1 and at Week 12

AUC(last) is defined as the area under the plasma concentration-time curve from time zero to time the last quantifiable concentration, computed using the linear up/log down trapezoidal rule. AUC(last) was computed for EP-022679 (a metabolite of EDP-305) on Day 1 and Week 12 for the samples collected according to the intensive sampling scheme for the participants in the PK Population.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and on Day 84 (Week 12)
Reported as:
Geometric mean · h*ng/mL
AUC(Last) of EP-022679 on Day 1 and at Week 12
h*ng/mLEDP-305 1 mgEDP-305 2.5 mg
Day 12.32 ± 137.545.09 ± 117
Week 127.14 ± 11322.5 ± 104
SecondaryMean Change From Baseline in Body Weight at Week 12

Body weight was measured at specific timepoints for the participants. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · kilograms (kg)
Mean Change From Baseline in Body Weight at Week 12
kilograms (kg)PlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Body Weight at Week 12-0.877 ± 2.8100-1.440 ± 2.7984-2.114 ± 3.2829
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.1120 · Ls mean difference: 1.356 · 95% CI -0.322 to 3.034
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.4229 · Ls mean difference: 0.647 · 95% CI -0.947 to 2.240
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.2764 · Ls mean difference: 0.710 · 95% CI -0.577 to 1.996
SecondaryMean Change From Baseline in Waist to Hip (WTH) Ratio at Week 12

The WTH ratio is calculated as the ratio of waist to hip circumference, which was measured at specific timepoints. Baseline refers to the last non-missing value collected prior to the first dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Baseline and Week 12
Reported as:
Mean · ratio
Mean Change From Baseline in Waist to Hip (WTH) Ratio at Week 12
ratioPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Waist to Hip (WTH) Ratio at Week 120.013 ± 0.0729-0.007 ± 0.04770.014 ± 0.0509
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.5606 · Ls mean difference: 0.008 · 95% CI -0.020 to 0.037
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.1002 · Ls mean difference: 0.023 · 95% CI -0.004 to 0.050
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.2002 · Ls mean difference: -0.014 · 95% CI -0.036 to 0.008
SecondaryMean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12

Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Reported as:
Mean · nanogram per liter (ng/L)
Mean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12
nanogram per liter (ng/L)PlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Fibroblast Growth Factor 19 (FGF19) by Nominal Timepoint (Intensive Pharmacodynamic [PD] Samples) at Week 12159.98 ± 165.245410.00 ± 260.223607.12 ± 891.553
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.7014 · Ls mean difference: -178.787 · 95% CI -1098.454 to 740.880
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.9070 · Ls mean difference: 52.307 · 95% CI -830.934 to 935.547
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.5360 · Ls mean difference: -231.094 · 95% CI -967.273 to 505.086
SecondaryMean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 12

Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: FGF19. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Reported as:
Mean · ng/L
Mean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 12
ng/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in FGF19 by Bin Timepoint (Sparse PD Samples) at Week 1233.51 ± 155.74446.04 ± 88.662813.29 ± 3200.567
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.2985 · Ls mean difference: -753.153 · 95% CI -2183.920 to 677.614
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.8413 · Ls mean difference: 139.107 · 95% CI -1236.689 to 1514.902
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.1168 · Ls mean difference: -892.260 · 95% CI -2011.705 to 227.186
SecondaryMean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12

Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Reported as:
Mean · ng/mL
Mean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12
ng/mLPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in 7a-Hydroxy-4-Cholestene-3-One (C4) by Nominal Timepoint (Intensive PD Samples) at Week 12-9.484 ± 20.6295-36.783 ± 24.6560-40.567 ± 20.9260
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = <0.0001 · Ls mean difference: 33.491 · 95% CI 17.984 to 48.998
  • Placebo vs EDP-305 1 mg · ANCOVA · p = <0.0001 · Ls mean difference: 30.814 · 95% CI 15.802 to 45.825
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.6757 · Ls mean difference: 2.677 · 95% CI -9.946 to 15.300
SecondaryMean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12

Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: C4. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Reported as:
Mean · ng/mL
Mean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12
ng/mLPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in C4 by Bin Timepoint (Sparse PD Samples) at Week 12-5.242 ± 30.5321-13.500 ± 26.2458-23.773 ± 20.7045
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0134 · Ls mean difference: 21.300 · 95% CI 4.533 to 38.067
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.4686 · Ls mean difference: 5.847 · 95% CI -10.116 to 21.811
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.0181 · Ls mean difference: 15.453 · 95% CI 2.699 to 28.206
SecondaryMean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 12

Blood samples were collected according to the intensive sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Predose and 2, 6, and 8 hours postdose on Day 1 and Day 84 (Week 12)
Reported as:
Mean · micromoles per liter (μmol/L)
Mean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 12
micromoles per liter (μmol/L)PlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in Bile Acid (BA) by Nominal Timepoint (Intensive PD Samples) at Week 124.47 ± 3.6682.16 ± 5.5070.14 ± 3.125
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.0557 · Ls mean difference: 4.324 · 95% CI -0.108 to 8.756
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.2867 · Ls mean difference: 2.305 · 95% CI -1.955 to 6.566
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.2437 · Ls mean difference: 2.019 · 95% CI -1.390 to 5.429
SecondaryMean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 12

Blood samples were collected according to the sparse sampling scheme at specific timepoints to assess the PD marker: BA. Baseline refers to the last non-missing predose value collected prior to the most recent dose of study treatment. Mean change was defined as the mean value at Week 12 minus the mean value at baseline.

Time frame:
Predose and two samples postdose (first sample between 1 to 3 hours postdose and second sample 1 hour later than fist sample) on Day 1 and Day 84 (Week 12)
Reported as:
Mean · μmol/L
Mean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 12
μmol/LPlaceboEDP-305 1 mgEDP-305 2.5 mg
Mean Change From Baseline in BA by Bin Timepoint (Sparse PD Samples) at Week 120.77 ± 5.789-0.11 ± 2.7830.74 ± 4.091
Statistical analysis
  • Placebo vs EDP-305 2.5 mg · ANCOVA · p = 0.9913 · Ls mean difference: 0.019 · 95% CI -3.491 to 3.530
  • Placebo vs EDP-305 1 mg · ANCOVA · p = 0.5530 · Ls mean difference: 0.995 · 95% CI -2.323 to 4.314
  • EDP-305 1 mg vs EDP-305 2.5 mg · ANCOVA · p = 0.4729 · Ls mean difference: -0.976 · 95% CI -3.665 to 1.713

Adverse events

Collected over Adverse events (AEs) were reported from the date of signing the consent form to the date of completion of the participant's end of the study visit (Week 16). Ongoing AEs were followed beyond the end of the study visit at the discretion of the investigator.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)1/24 (4.2%)8/24 (33.3%)
EDP-305 1 mg0/55 (0%)1/55 (1.8%)17/55 (30.9%)
EDP-305 2.5 mg0/53 (0%)0/53 (0%)32/53 (60.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboEDP-305 1 mgEDP-305 2.5 mg
Cerebrovascular accidentNervous system disorders1/240/550/53
AsthmaRespiratory, thoracic and mediastinal disorders0/241/550/53
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboEDP-305 1 mgEDP-305 2.5 mg
Pruritus generalisedSkin and subcutaneous tissue disorders1/245/5525/53
VomitingGastrointestinal disorders2/241/551/53
HeadacheNervous system disorders2/242/552/53
FatigueGeneral disorders2/242/552/53
RashSkin and subcutaneous tissue disorders0/241/554/53
PruritusSkin and subcutaneous tissue disorders1/240/553/53
DiarrhoeaGastrointestinal disorders0/242/553/53
CoughRespiratory, thoracic and mediastinal disorders0/241/553/53
NauseaGastrointestinal disorders1/243/552/53
Urinary tract infectionInfections and infestations0/243/551/53

Baseline characteristics

Demographics were summarized for the Safety Population, which included all the randomized participants who received at least one dose of the study treatment. The numbers of participants included in the Efficacy Population were same as the Safety Population.

Age, Customized
Age, Customized(Participants)PlaceboEDP-305 1 mgEDP-305 2.5 mgTotal
<65 years225246120
≥65 years23712
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEDP-305 1 mgEDP-305 2.5 mgTotal
Female11292969
Male13262463
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEDP-305 1 mgEDP-305 2.5 mgTotal
American Indian or Alaska Native1001
Asian17311
Black or African American2103
Native Hawaiian or Other Pacific Islander0000
White174247106
Not reported2215
Other0011
Mexican1113
Not specified0202
08

Study locations

82 sites
  • Radiant Research Incorporated
    Chandler, Arizona 85224, United States
  • Central Arizona Medical Associates
    Mesa, Arizona 58206, United States
  • Mayo Clinic Specialty Building
    Phoenix, Arizona 85054, United States
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • estudy site - Chula Vista
    Chula Vista, California 91911, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Fresno Clinical Research Center (FCRC)
    Fresno, California 93720, United States
  • UCSD Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • Inland Empire Liver Foundation
    Rialto, California 92377, United States
  • Southern California Transplantation Institute Research Foundation
    San Clemente, California 92673, United States
  • Precision Research Institute
    San Diego, California 92114, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Clinical Research Advantage, Inc. / Colorado Springs Family Practice
    Colorado Springs, Colorado 80909, United States
  • South Denver Gastroenterology,P.C.
    Englewood, Colorado 80113, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Jacksonville Center for Endoscopy - Southside ; Borland Groover Clinic
    Jacksonville, Florida 32226, United States
  • Precision Clinical Research, LLC.
    Lauderdale Lakes, Florida 33319, United States
  • Ocean Blue Medical Research Center, Inc
    Miami Springs, Florida 33166, United States
  • Homestead Medical Research
    Miami, Florida 33030, United States
  • Research Associates of South Florida, LLC
    Miami, Florida 33134, United States
  • Florida Advanced Medical Research, Inc.
    Miami, Florida 33144, United States
  • Clinical Neuroscience Solutions Inc.
    Orlando, Florida 32801, United States
  • Advanced Gastroenterology Associates, LLC
    Palm Harbor, Florida 34684, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Gastrointestinal Specialists Of Georgia
    Marietta, Georgia 30060, United States
  • Feinberg School of Medicine Northwestern University
    Chicago, Illinois 60611, United States
  • Midwest Institute For Clinical Research
    Indianapolis, Indiana 46260, United States
  • WestGlen Gastrointestinal Consultants, PA
    Shawnee Mission, Kansas 66217, United States
  • Oshsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Digestive Disease Associates, PA
    Catonsville, Maryland 21228, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Saint Louis University
    Saint Louis, Missouri 63104, United States
  • AGA Clinical Research Associates, LLC
    Egg Harbor Township, New Jersey 08234, United States
  • Northwell Health Inc.
    Manhasset, New York 11030, United States
  • NYU Langone Medical Center - The Center for Musculoskeletal Care (CMC)
    New York, New York 10016, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Carolinas Medical Center Transplant Center/Center for Liver Disease
    Charlotte, North Carolina 28204, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Carolinas Center for Liver Disease / Carolinas Health Care System
    Huntersville, North Carolina 28078, United States
  • Sterling Research Group, Ltd.
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pittsburgh Medical Center - Center for Liver Diseases
    Pittsburgh, Pennsylvania 15213, United States
  • University Of Tennessee Health Science Center
    Memphis, Tennessee 38104, United States
  • Quality Medical Research, PLLC
    Nashville, Tennessee 37211, United States
  • Texas Clinical Research Institute
    Arlington, Texas 76012, United States
  • Texas Diabetes & Endocrinology
    Austin, Texas 78749, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • DHAT Research Institute
    Garland, Texas 75044, United States
  • Baylor College of Medicine - Advanced Liver Therapies
    Houston, Texas 77030, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Radiant Research, Inc.
    San Antonio, Texas 78229, United States
  • Wasatch Peak Family Practice/Radiant Research, Inc
    Layton, Utah 84041, United States
  • Radiant Research, Inc.
    Murray, Utah 84123, United States
  • Gastroenterology Associates, PC
    Gainesville, Virginia 20155, United States
  • Bon Secours St. Mary's Hospital of Richmond, Inc
    Newport News, Virginia 23602, United States
  • The Gastroenterology Group, PC
    Reston, Virginia 20191, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Swedish Medical Center-Swedish Organ Transplant and Liver Center
    Seattle, Washington 98104, United States
  • University of Washington / Harborview Medical Center
    Seattle, Washington 98104, United States
  • Mayo Clinic Health System - Franciscan Healthcare
    La Crosse, Wisconsin 54601, United States
  • Aggarwal and Associates Limited
    Brampton, Ontario L6T OG1, Canada
  • Toronto Liver Centre
    Toronto, Ontario M6H3M1, Canada
  • Clinique de recherche Medpharmgene
    Montreal, Quebec H2K 1H2, Canada
  • Chronic Viral Illness Service McGill University Health Center/Royal Victoria
    Montreal, Quebec H4A 3JI, Canada
  • Hopital Pitie Salpetriere
    Paris, Cedex 13, France
  • CHU de Bordeaux - GH Sud - Hoital Haut Leveque
    Pessac, 33604, France
  • CHU de Strasbourg - Nouvel Hôspital Civil
    Strasbourg, 67000, France
  • Auckland Clinical Studies Limited
    Auckland, 1010, New Zealand
  • Latin Clinical Trial Center
    San Juan, PR 00909, Puerto Rico
  • Addenbrookes Hospital (AH)-Cambridge University Hospitals NHS Foundation Trust
    Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • King's College Hospital NHS Foundation
    London, Greater London SE5 9RS, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, Nottinghamshire NG7 2UH, United Kingdom
09

References and documents

Publications

  • Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, Denham D, Kayali Z, Sheikh A, Kowdley KV, Desta T, Elkhashab M, DeGrauw J, Goodwin B, Ahmad A, Adda N. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2022 Mar;76(3):506-517. doi: 10.1016/j.jhep.2021.10.018. Epub 2021 Nov 3. PubMed 34740705 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jun 2019, 13 months.

Results were first posted in Sep 2021, 2 years 3 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 13 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2018
First posted
Feb 5, 2018
StartActual
Apr 25, 2018
Primary completionActual
Jun 14, 2019
CompletionActual
Jul 10, 2019
Results first posted
Sep 16, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03421431
Collaborators
ICON Clinical Research, Triangle Biostatistics, LLC
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Apr 25, 2018
Primary completion
Jun 14, 2019
Completion
Jul 10, 2019
Results posted
Sep 16, 2021
Last update
Sep 16, 2021

Study contacts

Nathalie Adda, MD
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EDP-305

Start the discussion